The need for thorough phase II studies in medicines development for Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Gray, Julian A ^a   Fleet, David ^b   Winblad, Bengt ^c  

^a Neuroglobe Ltd   (Switzerland)

^b Datamagik Ltd   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CRENEZUMAB; DONEPEZIL; SOLANEZUMAB; TARENFLURBIL; PHARMACOLOGICAL BIOMARKER;

ALZHEIMER DISEASE; CLINICAL EFFECTIVENESS; CLINICAL STUDY; DRUG EFFICACY; DRUG SAFETY; EFFECT SIZE; HUMAN; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; TREATMENT RESPONSE; DRUG DEVELOPMENT; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES;

ALZHEIMER DISEASE; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DISCOVERY; HUMANS;

EID: 84945156205     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0153-y     Document Type: Review

References (18)

1. Cummings JL, Morstoff T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res Ther. 2014;6:37.
2. Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Internal Med. 2014;275:251-28.
3. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;1:40-51.
4. Becker RE, Greig NH. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res. 2010;7:642-51.
5. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76:185-205.
6. Chuang-Stein C, Kirby S. The shrinking or disappearing observed treatment effect. Pharmaceut Stat. 2014;13:277-80.
7. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther. 1997;61:275-91.
8. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomised, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996;7:293-303.
9. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021-31.
10. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136-45.
11. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer's disease a randomised controlled trial. JAMA. 2009;302:2557-64.
12. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer's Dement. 2009;5:388-97.
13. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
14. Cummings J, Cho W, Ward N, Friesenhahn M, Brunstein F, Honigberg L, et al. A randomised, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Alzheimer's Dement. 2014;10:275. http://www.alzheimersanddementia.com/article/S1552-5260%2814%2900578-0/abstract.
15. Food and Drugs Administration (FDA). Guidance for Industry (draft): Alzheimer's disease: developing drugs for the treatment of early stage disease. 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf.
16. th International Conference on Alzheimer's and Parkinson's diseases, Nice France, March 18-22, 2015. Neurodegener Dis. 2015;15:311. doi:10.1159/000381736.
17. Lai TL, Lavori PW, Shih MC. Sequential design of phase II-III cancer trials. Stat Med. 2012;31:1944-60.
18. Gray JA. Medicines Development in Alzheimer's disease, Supplement to Gray's Medicines Development. 2015. http://www.graybook.net/.